Status:
COMPLETED
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
Lead Sponsor:
Biogen
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
The primary objective of the study is to determine physician reported persistence with the Avonex PEN at Month 12/End of Study as well as determining factors associated with persistence. The secondary...
Eligibility Criteria
Inclusion
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent
- Must satisfy the locally approved therapeutic indications for the Avonex PEN
- Decision to treat with Avonex PEN must precede enrollment
- Must have no more than two (2) injections with the Avonex PEN prior to enrollment
Exclusion
- Inability to comply with study requirements
- Other unspecified reasons that, in the opinion of the investigator or Biogen Idec, make the patient unsuitable for enrollment
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT01405872
Start Date
September 1 2011
End Date
September 1 2013
Last Update
September 9 2014
Active Locations (64)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Glostrup Municipality, Denmark
2
Research Site
Holstebro, Denmark
3
Research Site
Næstved, Denmark
4
Research Site
Amiens, France